Equities
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (SEK)311.60
  • Today's Change3.60 / 1.17%
  • Shares traded2.20m
  • 1 Year change+22.24%
  • Beta0.2454
Data delayed at least 15 minutes, as of Aug 30 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Essity AB (publ) is a Sweden-based hygiene and health company that develops, produces, markets and sells personal care and tissue products. The Company conducts sales in about 150 countries under such brands, as TENA for incontinence products and Tork for Away-from-Home tissue, as well as under other brands, such as Bodyform, Velvet, Cushelle and Plenty. The Company’s medical brands comprise Leukoplast, Cutimed, JOBST, Delta Cast, Delta Lite and Actimove.

  • Revenue in SEK (TTM)131.76bn
  • Net income in SEK10.08bn
  • Incorporated1988
  • Employees36.01k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Essity AB (publ)131.76bn10.08bn218.78bn36.01k21.712.6213.111.6614.3527.21187.61118.840.65243.705.073,658,623.004.995.077.347.4933.8629.417.657.080.90689.150.368658.9712.054.4384.743.66-0.16276.15
Galderma Group AG44.33bn-145.80m237.29bn6.55k--3.0284.565.35-0.0508-0.050815.4427.30------560,582.40--------69.54---0.3266--0.92061.200.2786--7.65--40.97------
Beiersdorf AG109.91bn8.37bn367.95bn22.49k40.143.4930.593.353.263.2642.7137.470.7382.694.45441,114.805.716.388.288.9558.1457.237.748.601.34--0.062225.337.365.49-2.520.21887.637.39
Reckitt Benckiser Group Plc193.23bn20.82bn409.75bn40.00k20.123.7815.032.122.172.1720.0711.540.53143.496.58358,200.005.751.548.252.1060.5659.3210.813.370.469218.660.5237283.981.073.01-30.08-5.480.54332.43
Data as of Aug 30 2024. Currency figures normalised to Essity AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

30.17%Per cent of shares held by top holders
HolderShares% Held
MFS Institutional Advisors, Inc.as of 29 Dec 202335.13m5.48%
Norges Bank Investment Managementas of 29 Dec 202334.84m5.43%
Swedbank Robur Fonder ABas of 31 Jul 202428.84m4.50%
Handelsbanken Fonder ABas of 31 Jul 202422.33m3.48%
The Vanguard Group, Inc.as of 08 Aug 202421.66m3.38%
Nordea Investment Management ABas of 28 Jun 202412.71m1.98%
BlackRock Fund Advisorsas of 08 Aug 202411.50m1.79%
Carnegie Fonder ABas of 31 Jul 202410.37m1.62%
SEB Investment Management ABas of 31 Jul 20248.32m1.30%
F�rsta AP-fondenas of 30 Jun 20247.80m1.22%
More ▼
Data from 31 Mar 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.